biostudies-literatureUnknown16(1)Yuan Y<h4>Objective</h4>The purpose of our research was to investigate the clinical significance of lncRNA VIM anti-sense 1 (VIM-AS1) and to elucidate its cellular functions in breast cancer patients.<h4>Methods</h4>A cohort of one hundred and twenty-one individuals diagnosed with breast cancer and 95 healthy volunteers were recruited for this study. Relative abundances of VIM-AS1 were detected through quantitative real-time polymerase chain reaction (qRT-PCR). Receiver operating characteristic (ROC) was employed for evaluating the diagnosis potential of VIM-AS1. Kaplan-Meier method and Cox regression analysis was performed to further examine the prognostic performance of VIM-AS1. The cellular events of VIM-AS1 were assessed via CCK-8 and Transwell assay. The target interaction of VIM-AS1 and miDiscover oncology1807https://www.ebi.ac.uk/biostudies/studies/S-EPMC12495003biostudies-literatureLncRNA VIM-AS1 is a potential prognostic biomarker and effects on tumor cellular behaviors in breast cancer via impairing miR-29a-3p.PMC12495003Wei MKong LZhang HYuan QLi PBian WYuan YfalseLncRNA VIM-AS1 is a potential prognostic biomarker and effects on tumor cellular behaviors in breast cancer via impairing miR-29a-3p.<h4>Objective</h4>The purpose of our research was to investigate the clinical significance of lncRNA VIM anti-sense 1 (VIM-AS1) and to elucidate its cellular functions in breast cancer patients.<h4>Methods</h4>A cohort of one hundred and twenty-one individuals diagnosed with breast cancer and 95 healthy volunteers were recruited for this study. Relative abundances of VIM-AS1 were detected through quantitative real-time polymerase chain reaction (qRT-PCR). Receiver operating characteristic (ROC) was employed for evaluating the diagnosis potential of VIM-AS1. Kaplan-Meier method and Cox regression analysis was performed to further examine the prognostic performance of VIM-AS1. The cellular events of VIM-AS1 were assessed via CCK-8 and Transwell assay. The target interaction of VIM-AS1 and mi2025-01-01T00:00:00Z2025 Oct2026-05-31T03:16:15.799Z2026-05-31T03:06:42.246ZS-EPMC124950034104240610.1007/s12672-025-03568-y